NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Rituximab and Belimumab for Lupus Nephritis

Phase 2

Completed

Conditions: Lupus Nephritis

Interventions: Biological: Rituximab
Drug: Cyclophosphamide
Drug: Prednisone
Drug: Methylprednisolone
Drug: Diphenhydramine
Drug: Acetaminophen
Biological: Belimumab

First Posted Date: 2014-10-09

Last Posted Date: 2020-12-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 43

Registration Number: NCT02260934

Locations: 🇺🇸
University of Alabama, Birmingham, Birmingham, Alabama, United States
🇺🇸
UCLA Medical Center: Division of Rheumatology, Los Angeles, California, United States
🇺🇸
Colorado Kidney Care, Denver, Colorado, United States

and more 12 locations

Randomized, Open-label Phase 2 Study of Oral AZD0914 in the Treatment of Gonorrhea

Phase 2

Completed

Conditions: Gonorrhoea

Interventions: Drug: AZD0914
Drug: Ceftriaxone

First Posted Date: 2014-10-07

Last Posted Date: 2017-03-22

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 180

Registration Number: NCT02257918

Locations: 🇺🇸
Indiana University - Bell Flower Clinic, Indianapolis, Indiana, United States
🇺🇸
Durham County Health Department, Durham, North Carolina, United States
🇺🇸
Public Health STD Clinic, Seattle, Washington, United States

and more 2 locations

Novel Genetic Disorders of the Immune System

Recruiting

Conditions: MAGT1
PI3KCD
STAT3GOF
CTLA4

First Posted Date: 2014-10-07

Last Posted Date: 2025-03-30

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 500

Registration Number: NCT02257892

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Evaluating the Safety and Pharmacokinetics of VRC01, VRC01LS, and VRC07-523LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1-Exposed Infants

Phase 1

Completed

Conditions: HIV Infections

Interventions: Biological: VRC07-523LS
Biological: VRC01
Biological: VRC01LS

First Posted Date: 2014-10-03

Last Posted Date: 2023-02-08

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 83

Registration Number: NCT02256631

Locations: 🇿🇦
Famcru Crs, Tygerberg, Western Cape Province, South Africa
🇺🇸
Pediatric Perinatal HIV Clinical Trials Unit CRS, Miami, Florida, United States
🇺🇸
Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States

and more 11 locations

Retrospective Multicenter Study to Determine 4-Year Clinical Outcomes in Subjects Previously Enrolled in the CTOT-05 Study

Completed

Conditions: Cardiac Transplantation

First Posted Date: 2014-10-02

Last Posted Date: 2016-03-23

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 178

Registration Number: NCT02255123

Locations: 🇺🇸
Mount Sinai School of Medicine, New York, New York, United States
🇺🇸
Intermountain Medical Center, Murray, Utah, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 9 locations

A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine

Phase 1

Completed

Conditions: Avian Influenza
Immunisation

Interventions: Biological: Influenza Virus Vaccine, Live Attenuated H7N9 Anhui 2013/AA ca
Biological: Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013
Drug: MF59 adjuvant

First Posted Date: 2014-09-29

Last Posted Date: 2020-01-27

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 62

Registration Number: NCT02251288

Locations: 🇺🇸
University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States

Screening of Volunteers for Clinical Trials of Investigational or Licensed Vaccines or Antiviral Products

Completed

Conditions: Physiological Effects of Drugs
Antiviral Agents
Anti-Infective Agents
Vaccines
Immunologic Factors

First Posted Date: 2014-09-17

Last Posted Date: 2025-05-16

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 9

Registration Number: NCT02242968

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy

Phase 1

Completed

Conditions: Cat Allergy
Cat Hypersensitivity

Interventions: Biological: AMG 157
Biological: Cat Immunotherapy
Biological: Cat Immunotherapy Placebo
Biological: AMG 157 Placebo

First Posted Date: 2014-09-11

Last Posted Date: 2020-05-06

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 121

Registration Number: NCT02237196

Locations: 🇺🇸
Vital Prospects Clinical Research Institute, P.C., Tulsa, Oklahoma, United States
🇺🇸
Johns Hopkins Asthma & Allergy Center, Baltimore, Maryland, United States
🇺🇸
University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, United States

and more 6 locations

Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children

Phase 1

Completed

Conditions: Respiratory Syncytial Virus Infections

Interventions: Biological: RSV LID ΔM2-2 Vaccine
Biological: Placebo Vaccine

First Posted Date: 2014-09-11

Last Posted Date: 2015-10-08

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 29

Registration Number: NCT02237209

Locations: 🇺🇸
Usc La Nichd Crs, Alhambra, California, United States
🇺🇸
Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago, Illinois, United States
🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago (LCH) CRS, Chicago, Illinois, United States

and more 4 locations

People Presenting With Neurocysticercosis in North America

Terminated

Conditions: Neurocysticercosis

First Posted Date: 2014-09-09

Last Posted Date: 2018-04-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 11

Registration Number: NCT02233855

Locations: 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
🇺🇸
University of Washington, Seattle, Washington, United States

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy